United Therapeutics Corp
NASDAQ:UTHR

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
NASDAQ:UTHR
Watchlist
Price: 495.925 USD -0.87%
Market Cap: 21.4B USD
Section:
 

Relative Value

The Relative Value of one UTHR stock under the Base Case scenario is 380.583 USD. Compared to the current market price of 495.925 USD, United Therapeutics Corp is Overvalued by 23%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

UTHR Relative Value
Base Case
380.583 USD
Overvaluation 23%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.9
P/S
P/S
Price to Sales
6.9
vs History
0
vs Industry
61
Median 3Y
5.3
Median 5Y
5.2
Industry
7.9
Forward
6.5
More Details
16.9
P/E
P/E
Price to Earnings
16.9
vs History
22
vs Industry
10
Median 3Y
13.2
Median 5Y
14.4
Industry
23.7
Forward
17.8
More Details
13.8
P/OCF
P/OCF
Price to OCF
13.8
vs History
25
vs Industry
13
Median 3Y
11.9
Median 5Y
12.3
Industry
22
More Details
30.6
P/FCFE
P/FCFE
Price to FCFE
30.6
vs History
4
vs Industry
9
Median 3Y
19.9
Median 5Y
17.6
Industry
23.8
More Details
3.3
P/B
P/B
Price to Book Value
3.3
vs History
0
vs Industry
39
Median 3Y
2.1
Median 5Y
2.2
Industry
3.3
More Details
6
EV/S
EV/S
Enterprise Value to Sales
6
vs History
0
vs Industry
57
Median 3Y
4.2
Median 5Y
4.4
Industry
8.3
Forward
5.6
More Details
6.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.7
vs History
0
vs Industry
59
Median 3Y
4.7
Median 5Y
4.8
Industry
10.1
More Details
11.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
11.7
vs History
9
vs Industry
12
Median 3Y
8.1
Median 5Y
8.6
Industry
6.4
Forward
10.7
More Details
12.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.3
vs History
14
vs Industry
11
Median 3Y
8.5
Median 5Y
9.2
Industry
7
Forward
11.7
More Details
12
EV/OCF
EV/OCF
Enterprise Value to OCF
12
vs History
19
vs Industry
14
Median 3Y
9.8
Median 5Y
10.2
Industry
8.3
More Details
16.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
16.7
vs History
3
vs Industry
10
Median 3Y
12.2
Median 5Y
12.7
Industry
6.5
More Details
4.5
EV/IC
EV/IC
Enterprise Value to IC
4.5
vs History
0
vs Industry
40
Median 3Y
2.7
Median 5Y
2.6
Industry
5.7
More Details

Multiples Across Competitors

UTHR Competitors Multiples
United Therapeutics Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
United Therapeutics Corp
NASDAQ:UTHR
21.2B USD 6.9 16.9 11.7 12.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 738 486.8 -160 354 -194 720.9 -192 498.9
US
Abbvie Inc
NYSE:ABBV
396.8B USD 6.7 168.8 16.4 23.2
US
Amgen Inc
NASDAQ:AMGN
174B USD 4.8 25 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
150.7B USD 5.2 18.5 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.3B USD 9.9 31.4 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 088.1 -532.8 -580.2 -564.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79B USD 5.5 17.2 16.4 18.6
AU
CSL Ltd
ASX:CSL
85.8B AUD 3.7 19 12.8 16
NL
argenx SE
XBRU:ARGX
44.1B EUR 14.4 33.8 58.3 59.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.6B USD 16.1 1 191.4 155.5 188.6
P/E Multiple
Earnings Growth PEG
US
United Therapeutics Corp
NASDAQ:UTHR
Average P/E: 169.1
16.9
4%
4.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 354 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
19
11%
1.7
NL
argenx SE
XBRU:ARGX
33.8
40%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 191.4
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
United Therapeutics Corp
NASDAQ:UTHR
Average EV/EBITDA: 36
11.7
3%
3.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 720.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
58.3
839%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
155.5
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
United Therapeutics Corp
NASDAQ:UTHR
Average EV/EBIT: 41.4
12.3
7%
1.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 498.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
13%
1.4
AU
CSL Ltd
ASX:CSL
16
11%
1.5
NL
argenx SE
XBRU:ARGX
59.9
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
188.6
N/A N/A

See Also

Summary
UTHR intrinsic value, competitors valuation, and company profile.
DCF Valuation
UTHR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
UTHR stock valuation using valuation multiples.
Wall Street Estimates
UTHR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
UTHR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.